| Literature DB >> 35409101 |
Tania Bakshi1, David Pham2, Raminderjeet Kaur3, Bingyun Sun1,4.
Abstract
N-Glycosylation (NG) and disulfide bonds (DBs) are two prevalent co/post-translational modifications (PTMs) that are often conserved and coexist in membrane and secreted proteins involved in a large number of diseases. Both in the past and in recent times, the enzymes and chaperones regulating these PTMs have been constantly discovered to directly interact with each other or colocalize in the ER. However, beyond a few model proteins, how such cooperation affects N-glycan modification and disulfide bonding at selective sites in individual proteins is largely unknown. Here, we reviewed the literature to discover the current status in understanding the relationships between NG and DBs in individual proteins. Our results showed that more than 2700 human proteins carry both PTMs, and fewer than 2% of them have been investigated in the associations between NG and DBs. We summarized both these proteins with the reported relationships in the two PTMs and the tools used to discover the relationships. We hope that, by exposing this largely understudied field, more investigations can be encouraged to unveil the hidden relationships of NG and DBs in the majority of membranes and secreted proteins for pathophysiological understanding and biotherapeutic development.Entities:
Keywords: N-glycosylation; disulfide bonds; endoplasmic reticulum quality control; membrane and secreted proteins; posttranslational modifications; protein structure and function
Mesh:
Substances:
Year: 2022 PMID: 35409101 PMCID: PMC8998389 DOI: 10.3390/ijms23073742
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Distribution of species hosting proteins studied for N-glycosylation and disulfide bonds.
Figure 2Distribution of different relationships between the N-glycosylation and disulfide bonds in the literature examined.
Summary of the proteins showing interactions between N-glycosylation and disulfide bonds.
| UniProt Accession | Protein Name | Position of DBs | Position of | Class | Reference |
|---|---|---|---|---|---|
| A0A346IHA8 | CD4-binding region of the envelope glycoproteins | 50–70 a, 219–248 a, 229–240 a, 369–402 a, 362–429, 597–603 a | 390, 447 | No relation | [ |
| Q9Y6R1 | SLC4 Na+-coupled transporter (NBCe1-A) | 583–585, 630–642 c | 597, 617 | Inhibition | [ |
| Q99062 | Granulocyte colony-stimulating factor receptor | 107–118, 153–162, 224–271, 364–371 | 27, 69, 104, 110, 365, 450, 547, 555, 586 | Promotion | [ |
| Q62635 | Gastric mucin (rat) | 160 a, 420 a, 667 a, 767 a, 837 a, 892 a, 1136 a, 1151 a, 1212 a, 1227 a, 1243 a, 1350 a, | Promotion | [ | |
| P49018 | GPI-anchor transamidase (GPI8) yeast | 85 (interchain with C-194 in GPI16) b | 256 a, 346 a | Promotion | [ |
| P00750 | Tissue-type plasminogen activator (t-PA) | 41–71, 69–78, 86–97, 91–108, 110–119, 127–208 b, 148–190 b, 179–203 b, 215–296, 236–278, 267–291, 299–430, 342–358 b, 350–419 b, 444–519 b, 476–492 b, 509–537 b | 117, 184, 448 | Inhibition | [ |
| P04275 | Von Willebrand factor (VWF) | 35–162 d, 57–200 d, 388–524 d, 410–559 d, 432–440 d, 509–695, 767–808, 776–804, 810–821, 867–996 d, 889–1031 d, 898–993 d, 914–921 d, 1060–1084, 1071–1111, 1089–1091, 1126–1130, 1149–1169, 1153–1165, 1196–1199, 1234–1237, 1272–1458, 1669–1670, 1686–1872, 1879–1904, 1899–1940 d, 1927–2088, 1950–2085 d, 1972–2123 d, 1993–2001 d, 2724–2774 b, 2739–2788 b, 2750–2804 b, 2754–2806 b | 99 a, 156 a, 211 a, 666 a, 857 e, 1147 (atypical) e, 1231 e, 1515, 1574 e, 2223 e, 2290 e, 2357 e, 2400 e, 2546, 2585 e, 2790 e | Promotion | [ |
| P0DN86 | Human chorionic gonadotropin beta-subunit | 9–57, 23–72, 26–110, 34–88, 38–90, 93–100 | 13, 30 | Promotion | [ |
| Engineered heterodimeric knob-into-hole Fc fragments | 349–354 (interchain) | 297 | Promotion | [ | |
| P32906 | Yeast-alpha1,2 mannosidase | 340–385, 468–471 | 96, 155, 224 | Promotion | [ |
| O60896 | Receptor activity-modifying protein 3 (RAMP3) | 40–72 b, 57–104 b | 28, 57, 70, 102 | Inhibition | [ |
| Q13087 | PDIA2 | 18 (interchain) | 127, 284, 516 | Inhibition | [ |
| P04853 | Hemagglutinin-neuraminidase (Sendai virus) | 129 (interchain) a | 77, 499, 511 | Promotion | [ |
| Q91UL0 | Hemagglutinin-neuraminidase (NDV) | 123 (interchain), 172–196, 186–247, 238–251, 344–461, 455–465, 531–542 | 119, 341, 433, 481 | Inhibition | [ |
| Hemagglutinin (Influenza A virus) | 14–466, 52–277, 64–76, 97–139, 281–305, 473–477 | 8, 22, 38, 81, 165, 285, 483 | Promotion | [ | |
| P01229 | Human lutropin subunit beta | 29–77 b, 43–92 b, 46–130 b, 54–108 b, 58–110 b, 113–120 b | 30 | Promotion | [ |
| P35625 | Metalloproteinase inhibitor 3 (TIMP3) | 24–91, 26–118, 36–143, 145–192 d, 150–155 d, 163–184 d | Inhibition | [ | |
| Q16820 | Meprin A | 103–255, 124–144, 265–427, 273 a (interchain), 305 (interchain), 492 (interchain) d, 608–619 d, 613–628 d, 630–643 d | 41, 152, 234, 270, 330, 426, 452, 546, 553 | Promotion | [ |
| P01130 | Low-density lipoprotein (LDL) receptor | 27–39 e, 34–52 e, 46–63 e, 68–82 e, 75–95 e, 89–104 e, 109–121 b, 116–134 e, 128–143 e, 148–160 e, 155–173 e, 167–184 e, 197–209 e, 204–222 e, 216–231 e, 236–248 e, 243–261 e, 255–270 e, 276–289 e, 284–302 e, 296–313 e, 318–329 e, 325–338 e, 340–352 e, 358–368 e, 364–377 e, 379–392 e, 667–681 e, 677–696 e, 698–711 e | 97 a, 156, 272, 515 a, 657 | Inhibition | [ |
| Q02817 | MUC2 mucin | 59–67 b, 37–169 d, 59–206 d, 391–528 d, 413–563 d, 435–443 d, 860–992 d, 882–1027 d, 891–989 d, 909–916 d, 4481–4622 d, 4503–4661 d, 4527–4535 d, 5075–5122 b, 5089–5136 b, 5098–5152 b, 5102–5154 b | 163 a, 423 a, 670 a, 770 a, 894 a, 1139 a, 1154 a, 1215 a, 1230 a, 1246 a, 1787 a, 1820 a, 4339 a, 4351 a, 4362 a, 4373 a, 4422 a, 4438 a, 4502 a, 4616 a, 4627 a, 4752 a, 4787 a, 4881 a, 4888 a, 4955 a, 4970 a, 5019 a, 5038 a, 5069 a | Promotion | [ |
| P12476 | VP7 | 82–135, 165–249, 191–244, 196–207 | 69 | Promotion | [ |
| P04156 | Major prion protein | 179–214 | 181, 197 | Promotion | [ |
| P05026 | Sodium/potassium-transporting ATPase subunit beta-1 | 126–149, 159–175, 213–276 | 158, 193, 265 | Promotion | [ |
| P05231 | Interleukin-6 (IL6) | 45–51, 74–84 | 46 | Inhibition | [ |
| H2AM12 | Glycoprotein Gc | 523–550, 580–589, 591–598, 471–487 | 493, 686 | Promotion | [ |
| P22146 | 1,3-beta-Glucanosyltransferase | 74–103, 216–348, 234–265, 370–421, 372–462 b, 379–445 b, 398–403 b | 40 a, 57, 95 a, 149 a, 165 a, 253, 283 a, 321 a, 409 a, 495 a | Promotion | [ |
| P32623 | Probable glycosidase CRH2 | 28, 96 a, 190 a, 196 a, 233 a, 237 a, 261 a, 297 a, 310 a | Promotion | [ | |
| Q9UMF0 | Intercellular adhesion molecule-5 (ICAM5) | 55–99, 59–103, 142–198, 249–302 d, 344–383 d, 415–470 d, 498–552 d, 580–645 d, 673–725 d, 769–814 d | 54,74,137,195,214,274,316,371,397,582,636,645,762,793,794 | Promotion | [ |
| O75829 | Chondromodulin-I | 131–193 b, 282–286 b, 283–323 b, 293–317 b, 297–313 b | 243 a | No relation | [ |
| P40225 | Thrombopoietin | 7–151, 29–85 | 197, 206, 234, 255, 340 a, 348 a | No relation | [ |
| Q9UNQ0 | ABCG2 protein | 592–608, 603 (interchain) | 596 | Promotion | [ |
| P56817 | beta-Site APP-cleaving enzyme (BACE) | 216–420, 278–443, 330–380 | 153 a, 172 a, 223 a, 354 a | Promotion | [ |
| Q9H1U4 | Multiple epidermal growth factor-like domains protein 9 (MEGF9) | 204–217 a, 206–224 a, 226–235 a, 238–251 a, 254–266 a, 256–272 a, 274–283 a, 286–298 a, 301–310 a, 303–317 a, 320–329 a, 332–346 a, 349–360 a, 351–371 a, 374–383 a, 386–397 a, 400–415 a, 402–422 a, 425–434 a, 437–449 a | 40 a, 182 a, 205 a, 218 a, 245 a, 267 a, 305 a, 428 a, 468 a, 481 a, 500 a | Inhibition | [ |
| P53634 | Cathepsin | 30–118, 54–136 e, 255–298 e, 291–331 e, 321–337 e | 29 | Inhibition | [ |
| P08709 | Coagulation factor VII | 348–367 | 360 | Inhibition | [ |
| Q07837 | rBAT | 242–273, 571–666, 673–685 | 214, 261, 332, 495, 513, 575 | Promotion | [ |
| O75355 | Nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) | 92–116, 261–308, 289–334, 347–353, 399–422 | 81 a, 149 a, 238 a, 381 a, 392 a, 402 a, 454 a | Inhibition | [ |
| P08563 | E2 glycoprotein (rubella virus) | 53, 71, 115 | Promotion | [ | |
| Q9H9S5 | Fukutin-related protein (FKRP) | 6 (interchain) | 172, 209 | No relation | [ |
| O14773 | Tripeptidyl-peptidase I | 111–122, 365–526, 522–537 | 210, 222, 286, 313, 443 | Promotion | [ |
| P15813 | CD1d | 120–184, 224–279 | 20, 42, 108, 163 | Promotion | [ |
| O14656 | TorsinA | 44–162 a, 280–319 | 143, 158 | Promotion | [ |
| P21825 | Translocation protein SEC62 | 153, 62 e | Promotion | [ | |
| P04070 | Protein C | 331–345 | 97, 248, 313, 329 (atypical) | Promotion | [ |
| K7WJ21 | PtrMAN6 | 448, 452, 456 | 23, 194, 227, 375, 392 | No relation | [ |
| P01848/P01850 | TCR alpha and beta | 22–72, 94 (with C-130 in TRBC1 or TRBC2) and 30–95, 130 (with C-94 in TRAC) | 32, 66, 77 d, 113 d and 69 d | Inhibition | [ |
| P01857 | Immunoglobulin G1 Fc | 27–83 d, 103 e, 109 e, 112 e, 144–204 d, 250–308 d | 180, 297 | Promotion | [ |
| Nicotinic acetylcholine receptor fragment | 128–142 | 141 | Promotion | [ | |
| Q07108 | CD69 | 68 (interchain) e, 85–96 e, 113–194 e, 173–186 e | 111 (atypical), 166 | Inhibition | [ |
| P15813 | Antigen-presenting glycoprotein CD1d | 120–184 e, 224–279 e | 38 e, 60 e, 126 e, 181 e | Promotion | [ |
| P04439 | MHC class I heavy chain | 125–188 e, 227–283 e | 110 e | Promotion | [ |
a—predicted by sequence analysis (accessed from UniProt); b—by similarity (accessed from UniProt); c—a discrepancy between NG sites in the abstract and main text was found in [28]. We used the sites mentioned in the main text as they correspond with UniProt; d—PROSITE-ProRule annotation; e—UniProt.
Figure 3Schematic of the relative position between N-glycosylation and disulfide bonds and their relationship in the selected proteins discussed here. S4A4, UniProt ID of human SLC4 Na+-coupled transporter, NBCe1; CGB3, UniProt ID of human chorionic gonadotropin beta-subunit; 9HIV1, UniProt ID of human immunodeficiency virus envelope glycoprotein; CNMD, UniProt ID of human chondromodulin-1. Colors indicate different disulfide bond pairs. The N-glycan sign does not represent the actual sugar structure.
Summary of methodologies for the identification and structural analysis of N-glycosylation in proteins.
|
| Staining procedures [ | |
|
Resolve protein on SDS-PAGE and stain the gel for glycoproteins | ||
| Affinity-based methods [ | ||
|
Saccharide-binding protein (lectin-based) Enzyme-based methods Antibody-based methods | ||
| NMR spectroscopy [ | ||
| X-ray crystallography [ | ||
| Circular dichroism (CD) spectroscopy [ | ||
|
| Requires | Chromatography |
|
Enzymatic removal [ PNGase F Endo-H and peptide: Chemical removal [ β-Elimination Alkaline borohydride [ Hydrazinolysis |
Weak anion exchange (WAX) [ Gel filtration High-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) [ Normal-phase high-performance liquid chromatography (NP-HPLC) [ Reverse-phase HPLC (RP-HPLC) [ Mass spectrometry [ MALDI-MS, ESI-MS, or LC–ESI-MS [ LC–MS/MS [ Targeted MS/MS [ | |
|
| Chemical tools: inhibitors of glycosyltransferases and glycosidases (in vivo) [ | |
|
Tunicamycin Plant alkaloids: australine, castanospermine [ | ||
| Physical tools: adjust temperature, ATP, pH, etc. | ||
| Site-directed mutagenesis | ||
| Genetic glyco-engineering [ | ||
|
Involves introduction of heterologous glycosylation machinery or inactivation of endogenous enzymes. | ||
Summary of the methodologies for the detection and analysis of disulfide bonds in proteins.
|
| Chemical labeling and spectroscopic detection [ | |
|
Ellman assay | ||
|
| Reducing enzymes [ | |
|
2-Mercaptoethanol (ME) Dithiothreitol (DTT) Tris(2-carboxyethyl)phosphine (TCEP) Tris(2-hydroxyethyl)phosphine (THP) | ||
|
| Edman degradation sequencing [ | |
| NMR spectroscopy [ | ||
| X-ray crystallography [ | ||
| 2-Nitro-5-thiosulfobenzoate (NTSB) assay [ | ||
|
Electrophoretic methods [ Capillary electrophoresis sodium dodecyl sulfate (CE-SDS) Nonreducing SDS polyacrylamide gel electrophoresis (SDS-PAGE) [ Diagonal gel electrophoresis [ | ||
| Mass spectrometry approaches: | Mass spectrometry approaches: | |
|
LC–MS/MS LC–ESI-MS/MS ETD-MS/MS ESI-MS/MS MS/MS/MS |
Activated ion ETD (AI-ETD) [ CID [ HCD [ EThcD [ Ultraviolet photodissociation (UVPD)–MS [ | |
|
| Partial proteolysis by enzymes such as trypsin and pepsin | |
| Functional assays | ||
|
Epitope tags such as haemagglutinin, hexahistidine, V5, FLAG (visualized using antibodies) Biotin tags | ||
| Site-directed mutagenesis | ||
Figure 4Molecular pathophysiology of extracellular loop 3 of NBCe1-A caused by mutual relationships between N-glycosylation and disulfide bonds.